Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Kidney Transplantation | 11 | 2023 | 839 | 1.260 |
Why?
|
Kidney Failure, Chronic | 7 | 2023 | 365 | 1.230 |
Why?
|
Diabetes Mellitus, Type 2 | 9 | 2021 | 1085 | 1.190 |
Why?
|
Quality Improvement | 9 | 2022 | 413 | 1.180 |
Why?
|
Hospitalization | 12 | 2023 | 978 | 1.170 |
Why?
|
Health Care Costs | 14 | 2021 | 346 | 1.110 |
Why?
|
Primary Health Care | 11 | 2023 | 703 | 1.110 |
Why?
|
Medication Adherence | 5 | 2012 | 335 | 1.100 |
Why?
|
Length of Stay | 8 | 2023 | 780 | 1.030 |
Why?
|
Emergency Service, Hospital | 7 | 2023 | 711 | 0.970 |
Why?
|
Retrospective Studies | 44 | 2023 | 7277 | 0.900 |
Why?
|
Hypoglycemic Agents | 6 | 2012 | 362 | 0.890 |
Why?
|
Anti-Bacterial Agents | 9 | 2015 | 1026 | 0.870 |
Why?
|
Analgesics, Opioid | 9 | 2022 | 498 | 0.850 |
Why?
|
Humans | 124 | 2023 | 68618 | 0.790 |
Why?
|
Medical Record Linkage | 3 | 2016 | 42 | 0.770 |
Why?
|
Cost of Illness | 6 | 2021 | 206 | 0.770 |
Why?
|
Middle Aged | 58 | 2022 | 21147 | 0.750 |
Why?
|
Inpatients | 3 | 2020 | 208 | 0.740 |
Why?
|
Prescription Drug Monitoring Programs | 4 | 2021 | 34 | 0.720 |
Why?
|
Adult | 54 | 2023 | 21403 | 0.710 |
Why?
|
Medical Overuse | 2 | 2016 | 28 | 0.680 |
Why?
|
South Carolina | 21 | 2021 | 2752 | 0.670 |
Why?
|
Health Information Exchange | 2 | 2016 | 37 | 0.660 |
Why?
|
Data Collection | 2 | 2012 | 420 | 0.660 |
Why?
|
Female | 71 | 2022 | 38074 | 0.650 |
Why?
|
Tissue and Organ Procurement | 2 | 2021 | 164 | 0.650 |
Why?
|
Male | 64 | 2022 | 37321 | 0.640 |
Why?
|
Databases, Factual | 3 | 2020 | 622 | 0.630 |
Why?
|
Hospitals | 5 | 2023 | 265 | 0.630 |
Why?
|
Staphylococcal Infections | 2 | 2011 | 156 | 0.630 |
Why?
|
Hospital Mortality | 3 | 2020 | 384 | 0.620 |
Why?
|
Aged | 40 | 2022 | 14862 | 0.610 |
Why?
|
Hospital Costs | 10 | 2014 | 117 | 0.610 |
Why?
|
Gram-Negative Bacteria | 2 | 2009 | 55 | 0.600 |
Why?
|
Angioplasty, Balloon, Coronary | 12 | 2005 | 178 | 0.600 |
Why?
|
Abdominal Injuries | 4 | 2018 | 60 | 0.590 |
Why?
|
Wounds, Nonpenetrating | 4 | 2018 | 131 | 0.560 |
Why?
|
Coronary Artery Bypass | 9 | 2005 | 218 | 0.560 |
Why?
|
Veterans | 7 | 2012 | 904 | 0.560 |
Why?
|
Patient Discharge | 5 | 2022 | 294 | 0.540 |
Why?
|
Healthcare Disparities | 6 | 2023 | 378 | 0.530 |
Why?
|
Sphincter of Oddi Dysfunction | 5 | 2014 | 48 | 0.510 |
Why?
|
United States | 32 | 2022 | 7367 | 0.500 |
Why?
|
Risk Adjustment | 1 | 2015 | 49 | 0.490 |
Why?
|
Myocardial Infarction | 2 | 2020 | 807 | 0.480 |
Why?
|
Cross Infection | 4 | 2011 | 195 | 0.480 |
Why?
|
Graft Survival | 6 | 2019 | 465 | 0.480 |
Why?
|
Drug Resistance, Bacterial | 3 | 2010 | 98 | 0.470 |
Why?
|
Electronic Health Records | 6 | 2020 | 374 | 0.430 |
Why?
|
Liver Function Tests | 5 | 2019 | 114 | 0.430 |
Why?
|
Liver Diseases | 3 | 2019 | 193 | 0.410 |
Why?
|
Abdominal Pain | 4 | 2014 | 97 | 0.410 |
Why?
|
Biometry | 1 | 2012 | 72 | 0.410 |
Why?
|
Hospital-Physician Relations | 1 | 2012 | 5 | 0.410 |
Why?
|
Delirium | 2 | 2023 | 45 | 0.410 |
Why?
|
Stroke | 7 | 2017 | 2163 | 0.400 |
Why?
|
Liver Cirrhosis | 4 | 2023 | 301 | 0.400 |
Why?
|
Adolescent | 22 | 2022 | 8912 | 0.400 |
Why?
|
Blood Glucose | 3 | 2012 | 631 | 0.390 |
Why?
|
Hospital Information Systems | 1 | 2012 | 44 | 0.390 |
Why?
|
Vancomycin | 1 | 2011 | 60 | 0.390 |
Why?
|
Non-alcoholic Fatty Liver Disease | 2 | 2023 | 87 | 0.370 |
Why?
|
Coronary Disease | 10 | 2000 | 358 | 0.370 |
Why?
|
Data Interpretation, Statistical | 1 | 2012 | 329 | 0.370 |
Why?
|
Methicillin Resistance | 2 | 2008 | 45 | 0.370 |
Why?
|
Patient Acceptance of Health Care | 5 | 2019 | 468 | 0.370 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2011 | 92 | 0.370 |
Why?
|
Communication | 1 | 2012 | 329 | 0.330 |
Why?
|
Health Resources | 4 | 2017 | 76 | 0.330 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2009 | 62 | 0.330 |
Why?
|
Cost Savings | 5 | 2021 | 110 | 0.320 |
Why?
|
Hepatitis C | 2 | 2020 | 114 | 0.320 |
Why?
|
Staphylococcus aureus | 2 | 2008 | 175 | 0.320 |
Why?
|
Kidney Diseases | 1 | 2011 | 307 | 0.320 |
Why?
|
Aged, 80 and over | 13 | 2021 | 4848 | 0.320 |
Why?
|
Child, Preschool | 9 | 2021 | 3187 | 0.320 |
Why?
|
Health Expenditures | 4 | 2020 | 170 | 0.320 |
Why?
|
Young Adult | 14 | 2022 | 5717 | 0.310 |
Why?
|
Internal Medicine | 4 | 2018 | 118 | 0.310 |
Why?
|
Endovascular Procedures | 3 | 2017 | 366 | 0.310 |
Why?
|
Vancomycin Resistance | 1 | 2008 | 18 | 0.310 |
Why?
|
Enterococcus | 1 | 2008 | 29 | 0.310 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 2008 | 35 | 0.300 |
Why?
|
Child | 12 | 2022 | 6405 | 0.300 |
Why?
|
Multivariate Analysis | 11 | 2018 | 1046 | 0.300 |
Why?
|
Drug Resistance, Multiple, Bacterial | 3 | 2015 | 47 | 0.300 |
Why?
|
Pseudomonas aeruginosa | 4 | 2011 | 133 | 0.300 |
Why?
|
Health Services | 1 | 2008 | 87 | 0.300 |
Why?
|
Postoperative Complications | 4 | 2020 | 1615 | 0.290 |
Why?
|
Referral and Consultation | 4 | 2020 | 383 | 0.290 |
Why?
|
Cohort Studies | 10 | 2019 | 2358 | 0.280 |
Why?
|
Treatment Outcome | 16 | 2022 | 7029 | 0.280 |
Why?
|
Tissue Plasminogen Activator | 3 | 2017 | 296 | 0.280 |
Why?
|
Decision Support Techniques | 5 | 2018 | 191 | 0.280 |
Why?
|
Formularies as Topic | 1 | 2006 | 5 | 0.280 |
Why?
|
Methicillin | 1 | 2006 | 11 | 0.280 |
Why?
|
Patient-Centered Care | 2 | 2018 | 106 | 0.270 |
Why?
|
Sphincterotomy, Endoscopic | 4 | 2014 | 79 | 0.270 |
Why?
|
Prospective Studies | 13 | 2021 | 3705 | 0.260 |
Why?
|
Cholecystectomy | 3 | 2014 | 79 | 0.260 |
Why?
|
Metabolic Syndrome | 2 | 2021 | 191 | 0.250 |
Why?
|
Parkinson Disease | 1 | 2008 | 272 | 0.250 |
Why?
|
Infant | 6 | 2021 | 2891 | 0.250 |
Why?
|
Peripheral Arterial Disease | 2 | 2017 | 83 | 0.250 |
Why?
|
Linear Models | 4 | 2020 | 521 | 0.250 |
Why?
|
Risk Factors | 11 | 2022 | 5731 | 0.250 |
Why?
|
Vascular Surgical Procedures | 2 | 2017 | 168 | 0.240 |
Why?
|
Telephone | 3 | 2010 | 160 | 0.230 |
Why?
|
Delivery of Health Care | 2 | 2020 | 445 | 0.230 |
Why?
|
Insulin | 3 | 2012 | 619 | 0.230 |
Why?
|
Thrombolytic Therapy | 2 | 2017 | 233 | 0.230 |
Why?
|
Time Factors | 13 | 2019 | 4655 | 0.230 |
Why?
|
Incidence | 6 | 2022 | 1603 | 0.220 |
Why?
|
Medicare | 4 | 2021 | 319 | 0.220 |
Why?
|
Follow-Up Studies | 8 | 2019 | 3259 | 0.220 |
Why?
|
Drug Prescriptions | 2 | 2021 | 135 | 0.210 |
Why?
|
Graft Rejection | 4 | 2019 | 458 | 0.210 |
Why?
|
Patient Transfer | 2 | 2023 | 86 | 0.210 |
Why?
|
Trauma Centers | 3 | 2018 | 197 | 0.210 |
Why?
|
Models, Statistical | 2 | 2019 | 448 | 0.210 |
Why?
|
Drug Utilization | 4 | 2012 | 119 | 0.210 |
Why?
|
Quality-Adjusted Life Years | 2 | 2020 | 106 | 0.210 |
Why?
|
Practice Patterns, Physicians' | 6 | 2022 | 504 | 0.210 |
Why?
|
Subacute Care | 1 | 2022 | 11 | 0.210 |
Why?
|
Transaminases | 1 | 2022 | 21 | 0.200 |
Why?
|
Telemedicine | 3 | 2021 | 700 | 0.200 |
Why?
|
Gonorrhea | 1 | 2022 | 50 | 0.200 |
Why?
|
Severity of Illness Index | 4 | 2023 | 1851 | 0.200 |
Why?
|
Ciprofloxacin | 2 | 2015 | 30 | 0.200 |
Why?
|
Reimbursement Mechanisms | 1 | 2021 | 37 | 0.190 |
Why?
|
Cause of Death | 2 | 2020 | 241 | 0.190 |
Why?
|
Patient Admission | 2 | 2016 | 99 | 0.190 |
Why?
|
Age Factors | 7 | 2018 | 1864 | 0.190 |
Why?
|
Cost-Benefit Analysis | 6 | 2017 | 504 | 0.190 |
Why?
|
Policy | 1 | 2021 | 58 | 0.190 |
Why?
|
Regional Medical Programs | 1 | 2020 | 22 | 0.190 |
Why?
|
Hematinics | 1 | 2021 | 52 | 0.190 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 5 | 2014 | 348 | 0.180 |
Why?
|
Administration, Oral | 2 | 2012 | 411 | 0.180 |
Why?
|
Longitudinal Studies | 4 | 2022 | 1054 | 0.180 |
Why?
|
Intersectoral Collaboration | 1 | 2020 | 27 | 0.180 |
Why?
|
Breast Neoplasms | 4 | 2022 | 1536 | 0.180 |
Why?
|
Hospital Administration | 1 | 2020 | 43 | 0.180 |
Why?
|
Anemia | 1 | 2021 | 104 | 0.180 |
Why?
|
Acute Disease | 2 | 2020 | 658 | 0.180 |
Why?
|
Glomerular Filtration Rate | 2 | 2019 | 274 | 0.180 |
Why?
|
Comorbidity | 5 | 2016 | 1426 | 0.180 |
Why?
|
Vulnerable Populations | 1 | 2021 | 84 | 0.180 |
Why?
|
Pseudomonas Infections | 3 | 2011 | 83 | 0.180 |
Why?
|
Infant, Newborn | 6 | 2021 | 2455 | 0.170 |
Why?
|
Tonsillectomy | 1 | 2021 | 69 | 0.170 |
Why?
|
Patient Participation | 1 | 2021 | 146 | 0.170 |
Why?
|
Tacrolimus | 2 | 2018 | 127 | 0.170 |
Why?
|
Patient Selection | 3 | 2021 | 592 | 0.170 |
Why?
|
Efficiency | 1 | 2020 | 49 | 0.170 |
Why?
|
Morbidity | 1 | 2020 | 130 | 0.170 |
Why?
|
Proportional Hazards Models | 6 | 2019 | 792 | 0.170 |
Why?
|
Hepatitis C Antibodies | 1 | 2019 | 19 | 0.170 |
Why?
|
Survival Rate | 3 | 2018 | 1056 | 0.170 |
Why?
|
Health Policy | 1 | 2021 | 221 | 0.170 |
Why?
|
Escherichia coli | 2 | 2015 | 368 | 0.170 |
Why?
|
Insurance, Health | 2 | 2020 | 201 | 0.170 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2022 | 300 | 0.160 |
Why?
|
Labor Presentation | 1 | 1998 | 8 | 0.160 |
Why?
|
Internship and Residency | 2 | 2015 | 596 | 0.160 |
Why?
|
Physicians, Primary Care | 1 | 2019 | 46 | 0.160 |
Why?
|
Microbial Sensitivity Tests | 2 | 2011 | 226 | 0.160 |
Why?
|
Twins | 1 | 1998 | 42 | 0.160 |
Why?
|
Hospitals, University | 3 | 2016 | 169 | 0.160 |
Why?
|
Delivery, Obstetric | 1 | 1998 | 58 | 0.160 |
Why?
|
Fluoroquinolones | 2 | 2011 | 49 | 0.160 |
Why?
|
Liver Neoplasms | 1 | 2022 | 334 | 0.150 |
Why?
|
Chronic Disease | 2 | 2016 | 1330 | 0.150 |
Why?
|
Opioid-Related Disorders | 1 | 2022 | 298 | 0.150 |
Why?
|
Medicaid | 4 | 2012 | 302 | 0.150 |
Why?
|
Colon | 1 | 2018 | 168 | 0.150 |
Why?
|
Transplant Recipients | 1 | 2018 | 109 | 0.150 |
Why?
|
Immunosuppressive Agents | 2 | 2018 | 514 | 0.140 |
Why?
|
Outpatient Clinics, Hospital | 2 | 1996 | 69 | 0.140 |
Why?
|
Liver | 2 | 2021 | 1118 | 0.140 |
Why?
|
End Stage Liver Disease | 1 | 2018 | 60 | 0.140 |
Why?
|
Anti-Infective Agents | 2 | 2011 | 166 | 0.140 |
Why?
|
Pain, Postoperative | 2 | 2022 | 214 | 0.140 |
Why?
|
Continuity of Patient Care | 1 | 2018 | 170 | 0.140 |
Why?
|
Comprehensive Health Care | 1 | 2016 | 26 | 0.140 |
Why?
|
Aspartate Aminotransferases | 3 | 2023 | 87 | 0.140 |
Why?
|
Renal Insufficiency | 1 | 2017 | 121 | 0.140 |
Why?
|
Aftercare | 2 | 2021 | 114 | 0.140 |
Why?
|
Disability Evaluation | 3 | 2017 | 298 | 0.140 |
Why?
|
Quality Indicators, Health Care | 1 | 2017 | 136 | 0.130 |
Why?
|
Age Distribution | 2 | 2015 | 320 | 0.130 |
Why?
|
Academic Medical Centers | 2 | 2016 | 281 | 0.130 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 1996 | 123 | 0.130 |
Why?
|
Fibrinolytic Agents | 2 | 2017 | 377 | 0.130 |
Why?
|
Popliteal Artery | 1 | 2015 | 40 | 0.130 |
Why?
|
Ultrasonography | 1 | 2017 | 453 | 0.130 |
Why?
|
Escherichia coli Infections | 1 | 2015 | 47 | 0.120 |
Why?
|
Advance Directives | 1 | 2015 | 22 | 0.120 |
Why?
|
Patients | 1 | 1995 | 69 | 0.120 |
Why?
|
Marital Status | 1 | 2015 | 65 | 0.120 |
Why?
|
Poverty | 2 | 2015 | 219 | 0.120 |
Why?
|
Emergency Medical Services | 1 | 2017 | 225 | 0.120 |
Why?
|
Urinary Tract Infections | 1 | 2015 | 71 | 0.120 |
Why?
|
Economics, Hospital | 1 | 1994 | 15 | 0.120 |
Why?
|
Liver Transplantation | 1 | 2018 | 400 | 0.120 |
Why?
|
Feedback, Psychological | 1 | 2014 | 17 | 0.120 |
Why?
|
Sex Distribution | 1 | 2015 | 274 | 0.120 |
Why?
|
Heart Diseases | 1 | 1997 | 276 | 0.120 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2010 | 931 | 0.120 |
Why?
|
Tomography, X-Ray Computed | 3 | 2018 | 2324 | 0.120 |
Why?
|
Ischemia | 1 | 2015 | 229 | 0.120 |
Why?
|
Costs and Cost Analysis | 6 | 2014 | 193 | 0.120 |
Why?
|
Lower Extremity | 1 | 2015 | 153 | 0.120 |
Why?
|
Brain Ischemia | 2 | 2017 | 665 | 0.120 |
Why?
|
Mental Disorders | 2 | 2016 | 659 | 0.110 |
Why?
|
Health Status Indicators | 2 | 1997 | 117 | 0.110 |
Why?
|
Aphasia | 2 | 2014 | 119 | 0.110 |
Why?
|
Anesthesia, General | 1 | 2014 | 86 | 0.110 |
Why?
|
Models, Theoretical | 2 | 2016 | 384 | 0.110 |
Why?
|
Regression Analysis | 3 | 2015 | 737 | 0.110 |
Why?
|
Cardiac Surgical Procedures | 2 | 1999 | 450 | 0.110 |
Why?
|
Lymph Nodes | 2 | 2005 | 258 | 0.110 |
Why?
|
Canada | 2 | 2017 | 267 | 0.110 |
Why?
|
Cross-Sectional Studies | 4 | 2023 | 2279 | 0.110 |
Why?
|
Predictive Value of Tests | 5 | 2019 | 1465 | 0.110 |
Why?
|
Physician-Patient Relations | 1 | 2015 | 261 | 0.110 |
Why?
|
Risk Assessment | 4 | 2022 | 2007 | 0.100 |
Why?
|
Hospital Charges | 3 | 2014 | 60 | 0.100 |
Why?
|
Polypharmacy | 1 | 2012 | 31 | 0.100 |
Why?
|
Health Personnel | 1 | 1995 | 286 | 0.100 |
Why?
|
Hospitals, Teaching | 2 | 2016 | 65 | 0.100 |
Why?
|
Patient Care Team | 1 | 2014 | 311 | 0.100 |
Why?
|
Pneumococcal Vaccines | 1 | 2012 | 30 | 0.100 |
Why?
|
Mortality | 1 | 2012 | 163 | 0.100 |
Why?
|
Pneumococcal Infections | 1 | 2012 | 30 | 0.100 |
Why?
|
Outpatients | 1 | 2012 | 127 | 0.100 |
Why?
|
Accidental Falls | 1 | 2012 | 84 | 0.100 |
Why?
|
Influenza Vaccines | 1 | 2012 | 56 | 0.100 |
Why?
|
Precision Medicine | 1 | 2012 | 111 | 0.100 |
Why?
|
Random Allocation | 1 | 2012 | 442 | 0.100 |
Why?
|
Renal Dialysis | 2 | 2023 | 174 | 0.100 |
Why?
|
Influenza, Human | 1 | 2012 | 79 | 0.100 |
Why?
|
Education, Medical, Continuing | 1 | 2012 | 136 | 0.100 |
Why?
|
Psychiatry | 1 | 2012 | 112 | 0.100 |
Why?
|
Urban Population | 2 | 2011 | 255 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 1 | 2012 | 536 | 0.090 |
Why?
|
Creatinine | 1 | 2011 | 243 | 0.090 |
Why?
|
Waiting Lists | 2 | 2021 | 104 | 0.090 |
Why?
|
Evidence-Based Medicine | 2 | 2012 | 438 | 0.090 |
Why?
|
Pediatrics | 1 | 2014 | 341 | 0.090 |
Why?
|
Schizophrenia | 1 | 2012 | 206 | 0.090 |
Why?
|
Reproducibility of Results | 3 | 2018 | 2077 | 0.090 |
Why?
|
Fibrosis | 2 | 2023 | 371 | 0.090 |
Why?
|
Research Design | 5 | 2010 | 729 | 0.090 |
Why?
|
Deglutition Disorders | 1 | 2014 | 297 | 0.090 |
Why?
|
Enterobacteriaceae | 1 | 2010 | 29 | 0.090 |
Why?
|
Colonic Neoplasms | 1 | 2012 | 299 | 0.090 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2012 | 446 | 0.090 |
Why?
|
Relative Value Scales | 3 | 2000 | 8 | 0.090 |
Why?
|
Sensitivity and Specificity | 5 | 2018 | 1753 | 0.090 |
Why?
|
Breech Presentation | 2 | 2000 | 11 | 0.090 |
Why?
|
Health Care Sector | 2 | 1999 | 26 | 0.080 |
Why?
|
Alanine Transaminase | 2 | 2021 | 137 | 0.080 |
Why?
|
Models, Econometric | 3 | 2005 | 26 | 0.080 |
Why?
|
Enterocolitis, Pseudomembranous | 1 | 2009 | 14 | 0.080 |
Why?
|
Telefacsimile | 1 | 2009 | 6 | 0.080 |
Why?
|
Drug Therapy, Combination | 1 | 2011 | 649 | 0.080 |
Why?
|
Pharmacies | 1 | 2009 | 18 | 0.080 |
Why?
|
Videoconferencing | 1 | 2009 | 43 | 0.080 |
Why?
|
Version, Fetal | 2 | 2000 | 8 | 0.080 |
Why?
|
Hypertension | 1 | 2018 | 1535 | 0.080 |
Why?
|
Quality of Life | 4 | 2008 | 1515 | 0.080 |
Why?
|
Reminder Systems | 1 | 2009 | 39 | 0.080 |
Why?
|
Odds Ratio | 3 | 2017 | 880 | 0.080 |
Why?
|
Disease Outbreaks | 1 | 2009 | 83 | 0.080 |
Why?
|
Rural Health Services | 1 | 2009 | 101 | 0.080 |
Why?
|
Demography | 2 | 2021 | 279 | 0.080 |
Why?
|
Health Services Accessibility | 3 | 2009 | 581 | 0.080 |
Why?
|
Infection Control | 1 | 2009 | 101 | 0.080 |
Why?
|
Counseling | 1 | 2010 | 280 | 0.080 |
Why?
|
Prevalence | 3 | 2018 | 1619 | 0.080 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2012 | 767 | 0.080 |
Why?
|
Manometry | 3 | 2014 | 276 | 0.070 |
Why?
|
Rural Population | 1 | 2011 | 398 | 0.070 |
Why?
|
Socioeconomic Factors | 4 | 2012 | 955 | 0.070 |
Why?
|
Injury Severity Score | 2 | 2018 | 204 | 0.070 |
Why?
|
Pancreatic Fistula | 1 | 2007 | 23 | 0.070 |
Why?
|
SEER Program | 2 | 2021 | 153 | 0.070 |
Why?
|
Analysis of Variance | 1 | 2009 | 1040 | 0.070 |
Why?
|
Patient Education as Topic | 1 | 2010 | 425 | 0.070 |
Why?
|
Interviews as Topic | 1 | 2008 | 392 | 0.070 |
Why?
|
Prognosis | 4 | 2019 | 2093 | 0.070 |
Why?
|
Psychotherapy | 1 | 2009 | 253 | 0.070 |
Why?
|
Ofloxacin | 1 | 2006 | 15 | 0.070 |
Why?
|
Patient Credit and Collection | 1 | 2006 | 7 | 0.070 |
Why?
|
Behavior Therapy | 1 | 2009 | 297 | 0.070 |
Why?
|
Pancreatectomy | 1 | 2007 | 129 | 0.070 |
Why?
|
Levofloxacin | 1 | 2006 | 23 | 0.070 |
Why?
|
Health Behavior | 1 | 2010 | 458 | 0.070 |
Why?
|
Health Services Research | 2 | 2018 | 209 | 0.070 |
Why?
|
Pancreatitis, Chronic | 1 | 2007 | 168 | 0.060 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2005 | 53 | 0.060 |
Why?
|
Pregnancy | 4 | 2016 | 2334 | 0.060 |
Why?
|
Chi-Square Distribution | 2 | 2017 | 546 | 0.060 |
Why?
|
Depressive Disorder, Major | 1 | 2009 | 439 | 0.060 |
Why?
|
Pancreatitis | 2 | 2014 | 279 | 0.060 |
Why?
|
Colonography, Computed Tomographic | 1 | 2004 | 23 | 0.060 |
Why?
|
Managed Care Programs | 3 | 1999 | 45 | 0.060 |
Why?
|
Stroke Rehabilitation | 1 | 2008 | 335 | 0.060 |
Why?
|
Fees, Medical | 2 | 2000 | 9 | 0.050 |
Why?
|
Stents | 2 | 1998 | 657 | 0.050 |
Why?
|
Colonoscopy | 1 | 2004 | 156 | 0.050 |
Why?
|
Neoplasm Invasiveness | 1 | 2004 | 369 | 0.050 |
Why?
|
Registries | 2 | 2017 | 733 | 0.050 |
Why?
|
Infusions, Intravenous | 2 | 2017 | 334 | 0.050 |
Why?
|
Cystic Fibrosis | 1 | 2006 | 283 | 0.050 |
Why?
|
Physicians | 2 | 1996 | 324 | 0.050 |
Why?
|
Appendectomy | 1 | 2022 | 47 | 0.050 |
Why?
|
Cardiovascular Diseases | 2 | 1999 | 940 | 0.050 |
Why?
|
Georgia | 3 | 2000 | 161 | 0.050 |
Why?
|
Residence Characteristics | 2 | 2014 | 252 | 0.050 |
Why?
|
Preventive Health Services | 1 | 2022 | 86 | 0.050 |
Why?
|
Controlled Substances | 1 | 2021 | 5 | 0.050 |
Why?
|
Ecosystem | 1 | 2021 | 54 | 0.050 |
Why?
|
Forecasting | 2 | 2019 | 277 | 0.050 |
Why?
|
Stakeholder Participation | 1 | 2020 | 17 | 0.050 |
Why?
|
Sustained Virologic Response | 1 | 2020 | 11 | 0.050 |
Why?
|
Cesarean Section | 2 | 1998 | 101 | 0.050 |
Why?
|
Prescription Drug Misuse | 1 | 2021 | 35 | 0.050 |
Why?
|
Self Efficacy | 1 | 2021 | 199 | 0.050 |
Why?
|
Obstetrics and Gynecology Department, Hospital | 1 | 2000 | 11 | 0.050 |
Why?
|
Specialization | 1 | 2020 | 66 | 0.050 |
Why?
|
Pharmacists | 1 | 2021 | 125 | 0.040 |
Why?
|
Insurance Carriers | 1 | 2020 | 9 | 0.040 |
Why?
|
Ambulatory Care | 1 | 2022 | 340 | 0.040 |
Why?
|
Monitoring, Physiologic | 1 | 2021 | 219 | 0.040 |
Why?
|
Biopsy | 1 | 2021 | 540 | 0.040 |
Why?
|
Cholangiography | 1 | 1999 | 55 | 0.040 |
Why?
|
Kidney Function Tests | 1 | 2019 | 114 | 0.040 |
Why?
|
Cholelithiasis | 1 | 1999 | 66 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2004 | 561 | 0.040 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2009 | 1506 | 0.040 |
Why?
|
Cholecystectomy, Laparoscopic | 1 | 1999 | 59 | 0.040 |
Why?
|
Transplantation, Homologous | 1 | 2019 | 242 | 0.040 |
Why?
|
Antiviral Agents | 1 | 2020 | 211 | 0.040 |
Why?
|
Diseases in Twins | 1 | 1998 | 31 | 0.040 |
Why?
|
Sphincter of Oddi | 1 | 1998 | 51 | 0.040 |
Why?
|
Intensive Care, Neonatal | 1 | 1998 | 38 | 0.040 |
Why?
|
Alkaline Phosphatase | 1 | 2018 | 71 | 0.040 |
Why?
|
Models, Economic | 1 | 2018 | 69 | 0.040 |
Why?
|
Preoperative Period | 1 | 2018 | 50 | 0.040 |
Why?
|
Pregnancy Outcome | 1 | 1998 | 157 | 0.040 |
Why?
|
Endosonography | 1 | 1999 | 177 | 0.040 |
Why?
|
Technology Assessment, Biomedical | 1 | 1997 | 24 | 0.040 |
Why?
|
Nursing Research | 1 | 1998 | 40 | 0.040 |
Why?
|
Laparotomy | 1 | 2017 | 65 | 0.040 |
Why?
|
False Negative Reactions | 1 | 2017 | 63 | 0.040 |
Why?
|
Health Care Surveys | 1 | 2018 | 239 | 0.040 |
Why?
|
Fee-for-Service Plans | 1 | 1997 | 24 | 0.040 |
Why?
|
Atherectomy, Coronary | 1 | 1997 | 5 | 0.040 |
Why?
|
Insurance, Health, Reimbursement | 1 | 1997 | 47 | 0.040 |
Why?
|
Europe | 1 | 2017 | 196 | 0.040 |
Why?
|
Lung Diseases | 1 | 1998 | 175 | 0.040 |
Why?
|
Angiography | 1 | 2017 | 194 | 0.040 |
Why?
|
Reoperation | 1 | 2018 | 467 | 0.030 |
Why?
|
Organizational Innovation | 1 | 2016 | 55 | 0.030 |
Why?
|
Cardiac Catheterization | 2 | 1996 | 419 | 0.030 |
Why?
|
Patient Identification Systems | 1 | 2016 | 18 | 0.030 |
Why?
|
Fee Schedules | 1 | 1996 | 2 | 0.030 |
Why?
|
Medicare Part B | 1 | 1996 | 3 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2017 | 567 | 0.030 |
Why?
|
Australia | 1 | 2017 | 235 | 0.030 |
Why?
|
Hospitals, Public | 1 | 2016 | 22 | 0.030 |
Why?
|
Coronary Angiography | 3 | 1996 | 866 | 0.030 |
Why?
|
International Classification of Diseases | 1 | 2016 | 85 | 0.030 |
Why?
|
Patient Compliance | 1 | 2018 | 402 | 0.030 |
Why?
|
Equipment and Supplies | 1 | 1995 | 18 | 0.030 |
Why?
|
Ultrasonography, Interventional | 1 | 1996 | 119 | 0.030 |
Why?
|
Limb Salvage | 1 | 2015 | 39 | 0.030 |
Why?
|
Embolization, Therapeutic | 1 | 2017 | 150 | 0.030 |
Why?
|
Cardiology | 1 | 1997 | 140 | 0.030 |
Why?
|
Pilot Projects | 2 | 2010 | 1342 | 0.030 |
Why?
|
Health Status Disparities | 1 | 2018 | 326 | 0.030 |
Why?
|
Disease-Free Survival | 1 | 2015 | 349 | 0.030 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 951 | 0.030 |
Why?
|
Dysarthria | 1 | 2014 | 9 | 0.030 |
Why?
|
Economics, Medical | 1 | 1994 | 8 | 0.030 |
Why?
|
Value of Life | 1 | 1994 | 14 | 0.030 |
Why?
|
Catheterization | 1 | 1995 | 209 | 0.030 |
Why?
|
Long-Term Care | 1 | 2014 | 53 | 0.030 |
Why?
|
Urban Health | 1 | 2014 | 49 | 0.030 |
Why?
|
Narcotics | 1 | 2014 | 65 | 0.030 |
Why?
|
Rural Health | 1 | 2014 | 66 | 0.030 |
Why?
|
Surveys and Questionnaires | 2 | 2010 | 2800 | 0.030 |
Why?
|
Patient Readmission | 1 | 2016 | 267 | 0.030 |
Why?
|
Pregnancy Complications | 1 | 2016 | 286 | 0.030 |
Why?
|
Attitude of Health Personnel | 1 | 2016 | 442 | 0.030 |
Why?
|
Postoperative Period | 1 | 2014 | 238 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 710 | 0.030 |
Why?
|
Educational Measurement | 1 | 2015 | 254 | 0.030 |
Why?
|
Education, Medical, Graduate | 1 | 2015 | 214 | 0.030 |
Why?
|
Neoplasm Staging | 2 | 2005 | 800 | 0.030 |
Why?
|
Survivors | 1 | 2014 | 256 | 0.020 |
Why?
|
Logistic Models | 1 | 2015 | 1420 | 0.020 |
Why?
|
Nurse Practitioners | 1 | 2012 | 90 | 0.020 |
Why?
|
Social Class | 2 | 2006 | 127 | 0.020 |
Why?
|
Penicillanic Acid | 1 | 2011 | 3 | 0.020 |
Why?
|
Piperacillin | 1 | 2011 | 6 | 0.020 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2014 | 782 | 0.020 |
Why?
|
Health Status | 1 | 2014 | 429 | 0.020 |
Why?
|
Tobramycin | 1 | 2011 | 38 | 0.020 |
Why?
|
Cephalosporins | 1 | 2011 | 59 | 0.020 |
Why?
|
Risk | 1 | 2012 | 563 | 0.020 |
Why?
|
Curriculum | 1 | 2015 | 575 | 0.020 |
Why?
|
Anxiety | 1 | 2014 | 422 | 0.020 |
Why?
|
Sex Factors | 1 | 2014 | 1266 | 0.020 |
Why?
|
Enterobacteriaceae Infections | 1 | 2010 | 25 | 0.020 |
Why?
|
Pamphlets | 1 | 2010 | 27 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 1993 | 378 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2010 | 186 | 0.020 |
Why?
|
Mass Screening | 1 | 1996 | 843 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2014 | 1738 | 0.020 |
Why?
|
Algorithms | 1 | 2015 | 1196 | 0.020 |
Why?
|
Hawaii | 1 | 2009 | 24 | 0.020 |
Why?
|
Hand Disinfection | 1 | 2009 | 9 | 0.020 |
Why?
|
Sanitation | 1 | 2009 | 5 | 0.020 |
Why?
|
Clinical Pharmacy Information Systems | 1 | 2009 | 8 | 0.020 |
Why?
|
Insurance, Pharmaceutical Services | 1 | 2009 | 12 | 0.020 |
Why?
|
Patient Isolation | 1 | 2009 | 35 | 0.020 |
Why?
|
Bacterial Toxins | 1 | 2009 | 50 | 0.020 |
Why?
|
Directive Counseling | 1 | 2009 | 23 | 0.020 |
Why?
|
Pain Management | 1 | 2010 | 186 | 0.020 |
Why?
|
Infusions, Intra-Arterial | 1 | 2008 | 27 | 0.020 |
Why?
|
Survival Analysis | 2 | 2004 | 714 | 0.020 |
Why?
|
Mental Health Services | 1 | 2009 | 199 | 0.020 |
Why?
|
Pain | 1 | 2010 | 472 | 0.020 |
Why?
|
Depression | 1 | 2014 | 943 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2004 | 1553 | 0.020 |
Why?
|
Program Evaluation | 1 | 2009 | 502 | 0.020 |
Why?
|
Diagnosis-Related Groups | 1 | 2006 | 28 | 0.020 |
Why?
|
Social Justice | 1 | 2006 | 32 | 0.020 |
Why?
|
Motivation | 1 | 2010 | 561 | 0.020 |
Why?
|
Statistical Distributions | 1 | 2005 | 8 | 0.020 |
Why?
|
Evaluation Studies as Topic | 2 | 1996 | 219 | 0.020 |
Why?
|
Selection Bias | 1 | 2005 | 23 | 0.020 |
Why?
|
Benchmarking | 1 | 2005 | 91 | 0.020 |
Why?
|
Bone Marrow | 1 | 2005 | 168 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2005 | 274 | 0.020 |
Why?
|
Axilla | 1 | 2004 | 36 | 0.010 |
Why?
|
Biomarkers | 1 | 2010 | 1593 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 2005 | 306 | 0.010 |
Why?
|
RNA, Neoplasm | 1 | 2004 | 76 | 0.010 |
Why?
|
Lymph Node Excision | 1 | 2004 | 91 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 2004 | 191 | 0.010 |
Why?
|
Reference Values | 1 | 2004 | 579 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2004 | 1174 | 0.010 |
Why?
|
Hospitals, Urban | 1 | 2000 | 46 | 0.010 |
Why?
|
Angina, Unstable | 1 | 2000 | 50 | 0.010 |
Why?
|
Angina Pectoris | 1 | 2000 | 61 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2000 | 306 | 0.010 |
Why?
|
Medical Laboratory Science | 1 | 1999 | 8 | 0.010 |
Why?
|
Physician's Role | 1 | 2000 | 116 | 0.010 |
Why?
|
Unnecessary Procedures | 1 | 1999 | 49 | 0.010 |
Why?
|
Cardiovascular Agents | 1 | 1999 | 82 | 0.010 |
Why?
|
Intraoperative Care | 1 | 1999 | 91 | 0.010 |
Why?
|
Professional Competence | 1 | 1999 | 100 | 0.010 |
Why?
|
Least-Squares Analysis | 1 | 1997 | 35 | 0.010 |
Why?
|
Capitation Fee | 1 | 1997 | 4 | 0.010 |
Why?
|
Cost Control | 1 | 1997 | 34 | 0.010 |
Why?
|
New Jersey | 1 | 1996 | 8 | 0.010 |
Why?
|
Medical Staff, Hospital | 1 | 1995 | 44 | 0.010 |
Why?
|
Chest Pain | 1 | 1995 | 151 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 1999 | 772 | 0.010 |
Why?
|
Recurrence | 1 | 1997 | 948 | 0.010 |
Why?
|
Policy Making | 1 | 1994 | 51 | 0.010 |
Why?
|
Mammography | 1 | 1996 | 310 | 0.010 |
Why?
|
Clinical Competence | 1 | 1996 | 657 | 0.010 |
Why?
|
Heart Failure | 1 | 1995 | 1180 | 0.000 |
Why?
|